Significant differences were observed in WHO grade, IDH status, 1p/19q codeletion, age, histological classification, OS, DSS, and PFI between glioma patients with high and low PTX3 expression levels (Figs. 8A–8H). The gene discussed is PTX3; the disease is central nervous system cancer.